Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

BACKGROUND: The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past, including routine differential blood counts, T cell subset distribution patte...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaißler, Andrea, Bochem, Jonas, Spreuer, Janine, Ottmann, Shannon, Martens, Alexander, Amaral, Teresa, Wagner, Nikolaus Benjamin, Claassen, Manfred, Meier, Friedegund, Terheyden, Patrick, Garbe, Claus, Eigentler, Thomas, Weide, Benjamin, Pawelec, Graham, Wistuba-Hamprecht, Kilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254874/
https://www.ncbi.nlm.nih.gov/pubmed/37286306
http://dx.doi.org/10.1136/jitc-2023-006802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254874/
https://www.ncbi.nlm.nih.gov/pubmed/37286306
http://dx.doi.org/10.1136/jitc-2023-006802

Ejemplares similares